Repertoire partners with Genentech in $765M deal to develop T cell-targeted autoimmune therapies

Cambridge, MA, April 22, 2025 (PRNewswire) -- Repertoire Immune Medicines has entered into a strategic partnership with Genentech to co-develop next-generation therapies for autoimmune diseases. At the core of the collaboration is Repertoire’s DECODE™ platform, which enables precision targeting of T cells. The deal includes an initial $35 million payment to Repertoire, with the potential for up to $730 million in development and commercialization milestones, in addition to tiered royalties on future sales.

Read full article here.